| 2025-11-05 |
详情>>
股本变动：
变动后总股本8559.04万股
变动原因 ▼▲
- 原因：
- From June 30, 2025 to September 30, 2025
Issuance of common stock, net
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.5美元,归母净利润-1.03亿美元,同比去年增长-99.26%
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-0.87美元,归母净利润-5546.3万美元,同比去年增长-52.87%
|
| 2025-04-30 |
详情>>
业绩披露：
2025年一季报每股收益-0.46美元,归母净利润-2928.1万美元,同比去年增长-99.82%
|
| 2025-04-11 |
股东大会：
将于2025-05-13召开股东大会
会议内容 ▼▲
- 1.Election of the director nominee set forth in the attached 2025 Annual Meeting Proxy Statement (the “Proxy Statement”) to serve as a Class II director, whose term will expire at the 2028 Annual Meeting of Stockholders;
2.Approval, on an advisory basis, of the compensation of our named executive officers in 2024;
3.Ratification of the appointment of PricewaterhouseCoopers LLP (“PwC”) as our independent registered public accounting firm for the 2025 fiscal year;
4.Any other matters that may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2025-03-24 |
详情>>
业绩披露：
2024年年报每股收益-1.32美元,归母净利润-8060.4万美元,同比去年增长-118.15%
|
| 2025-01-22 |
详情>>
内部人交易：
Shankar Gopi等共交易4笔
|
| 2024-12-16 |
复牌提示：
2024-12-16 09:54:33 停牌，复牌日期 2024-12-16 10:04:34
|
| 2024-10-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.86美元,归母净利润-5178万美元,同比去年增长-116.15%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.62美元,归母净利润-3628.1万美元,同比去年增长-143.63%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.27美元,归母净利润-1465.4万美元,同比去年增长-124.55%
|
| 2024-04-29 |
股东大会：
将于2024-05-29召开股东大会
会议内容 ▼▲
- 1.Election of the two director nominees set forth in the attached 2024 Annual Meeting Proxy Statement (the “Proxy Statement”) to serve as Class I directors, whose terms will expire at the 2027 Annual Meeting of Stockholders;
2.Approval, on an advisory basis, of the compensation of our named executive officers in 2023;
3.Ratification of the appointment of PricewaterhouseCoopers LLP (“PwC”) as our independent registered public accounting firm for the 2024 fiscal year;
4.Approval of an amendment to our Ninth Amended and Restated Certificate of Incorporation, as amended, to reflect Delaware law provisions regarding officer exculpation;
5.Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 4;
6.Any other matters that may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-03-14 |
详情>>
业绩披露：
2023年年报每股收益-0.84美元,归母净利润-3694.9万美元,同比去年增长-4.51%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.55美元,归母净利润-2395.6万美元,同比去年增长7.61%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-0.34美元,归母净利润-1489.2万美元,同比去年增长15.43%
|
| 2023-04-11 |
股东大会：
将于2023-05-09召开股东大会
会议内容 ▼▲
- 1.The election of the three director nominees set forth in the attached 2023 Annual Meeting Proxy Statement (the “Proxy Statement”) to serve as Class III directors, whose terms will expire in 2026;
2.The approval, on an advisory basis, of the compensation of our named executive officers in 2022;
3.The ratification of the appointment of PricewaterhouseCoopers LLP (“PwC”) as our independent registered public accounting firm for the 2023 fiscal year;
4.Any other matters that may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-04-12 |
股东大会：
将于2022-05-10召开股东大会
会议内容 ▼▲
- 1.the election of the director nominee set forth in the attached 2022 Annual Meeting Proxy Statement (the “Proxy Statement”) to serve as a Class II director, whose term will expire in 2025;
2.the approval, on an advisory basis, of the compensation of our named executive officers in 2021;
3.the ratification of the appointment of PricewaterhouseCoopers LLP (“PwC”) as our independent registered public accounting firm for the 2022 fiscal year;
4.any other matters that may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-14 |
股东大会：
将于2021-05-12召开股东大会
会议内容 ▼▲
- 1.to elect the two director nominees that are set forth in the attached Proxy Statement (the “Proxy Statement”) to serve as Class I directors, whose term will expire in 2024;
2.to approve, on an advisory basis, the compensation of our named executive officers in 2020;
3.to ratify the appointment of PricewaterhouseCoopers LLP (“PwC”) as our independent registered public accounting firm for the 2021 fiscal year;
4.to transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-08-19 |
股东大会：
将于2020-09-29召开股东大会
会议内容 ▼▲
- 1.Approve the Larimar Therapeutics, Inc. 2020 Equity Incentive Plan and certain conditional grants thereunder.
|
| 2019-04-26 |
股东大会：
将于2019-06-13召开股东大会
会议内容 ▼▲
- 1.to elect two directors, Peter Barrett, Ph.D. and Wendy Everett, Sc.D. to serve as Class II directors until the 2022 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation, or removal;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.to transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.
|
| 2018-04-18 |
股东大会：
将于2018-06-06召开股东大会
会议内容 ▼▲
- 1.to elect three directors, Thomas O. Daniel, M.D., Cameron Geoffrey McDonough, M.D., and Robert J. Perez to serve as Class I directors until the 2021 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation, or removal;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.to transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.
|
| 2017-04-28 |
股东大会：
将于2017-06-21召开股东大会
会议内容 ▼▲
- 1.to elect three directors, Thomas E. Hughes, Ph.D., John L. LaMattina, Ph.D. and Frank E. Thomas to serve as Class III directors until the 2020 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation, or removal;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.to transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.
|
| 2016-05-04 |
股东大会：
将于2016-06-30召开股东大会
会议内容 ▼▲
- 1.to elect three directors, Peter Barrett, Ph.D., Frances K. Heller and Bruce Booth, Ph.D. to serve as Class II directors until the 2019 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3.to transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.
|